CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for GSK plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

GSK plc
980 Great West Road
Phone: +44 2080475000p:+44 2080475000 BRENTFORD, TW8 9GS  United Kingdom Ticker: GSKGSK

Business Summary
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-YesYes--

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Non-Executive Chairman of the Board Jonathan R.Symonds 64 9/1/2019 9/1/2019
Chief Executive Officer, Executive Director Emma N.Walmsley 55 4/1/2017 10/1/2011
Chief Financial Officer, Executive Director JulieBrown 62 5/1/2023 4/3/2023
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
GLAXO SMITHKLINE PHILS. INC. INES
GSK Capital B.V. Netherlands
GSK Consumer Healthcare Holdings (No.2) Limited United Kingdom
38 additional Subsidiary records available in full report.

Business Names
Business Name
1506369 Alberta ULC
Action Potential Venture Capital Limited
Adechsa GmbH
437 additional Business Names available in full report.

General Information
Number of Employees: 70,212 (As of 12/31/2023)
Outstanding Shares: 4,145,099,701 (As of 10/31/2024)
Shareholders: 61,745
Stock Exchange: LON
Federal Tax Id: 000005710
Fax Number: +44 2080477807


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024